The formulation containing HPMC K15MCR and Polyox WSR at the Sorry, there is no online preview for this file type. Ranitidine can be found in many pharmaceutical firms such as tablets, injectable solutions and oral Dissolution enhancement of aceclofenac tablet by solid dispersion technique. short biological half life demands continuous intravenous infusion or time spaced injection. We chose tristearin as solid lipid and formulated it in nanoparticulate form by an ultrasonic Sorry, there is no online preview for this file type. Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Injectable. Moderate. REACTION TO SEPTRIN PROPHYLAXIS IN A NEWLY STARTED SWEATING WITH CHANGE IN HAEMODYNAMIC STABILITY. 1. 1 Injectable. Mild. 2. ORAL DICLOFENAC 50MG, HAEMOPTYSIS.
| Author: | Akinogami Vurisar |
| Country: | Azerbaijan |
| Language: | English (Spanish) |
| Genre: | Medical |
| Published (Last): | 8 December 2012 |
| Pages: | 284 |
| PDF File Size: | 7.88 Mb |
| ePub File Size: | 14.65 Mb |
| ISBN: | 900-6-51578-804-9 |
| Downloads: | 16716 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | Maramar |
The results of solubility studies are presented in Table 2. Its effects on cell adhesion molecular from neurophils have also been noted. In vitro data indicate inhibition of cyclooxygenase Cox -l and 2 by aceclofenac in whole bipod assays, with selectivity for Cox-2 being evident. One potential solution to this problem is to provide a dry reconstitutable Aceclofenac formulation which is mixed with a liquid vehicle just prior to administration but this too is not stable for longer period.
The process of claim 26wherein at least one of said non aqueous solubilizer component and said Aceclofenac salt stabilizer component is polyethylene glycol.
The lyophilized injections were reconstituted by adding WFI and were subjected to dilution studies for precipitation, if any with normal saline 0. Subjects undergoing treatment with a composition of the invention can be routinely monitored by any of the methods well known in the art to determine effectiveness of therapy. For the reduction in pain levels from baseline there was also evidence for superiority of aceclofenac compared with diclofenac resinate in terms of statistical significance, although this difference was not considered clinically relevant.
II Physical stability study of formulated lyophilized injection of aceclofenac. A stable injectable pharmaceutical composition as in claim 1, wherein aceckofenac aqueous solution of arginine and aceclofenac having pH of about 6. Accordingly, the objects and advantages of the present invention are described as below:. Disodium hydrogen phosphate dihydrate and sodium dihydrogen phosphate monohydrate were dissolved to it under stirring.
US20090156670A1 – Nonaqueous liquid parenteral aceclofenac formulation – Google Patents
A process for preparing a nonaqueous liquid parenteral Aceclofenac formulation for pharmaceutical application, which process comprises the steps of: In addition, aceclofenac was found to be highly active against sodium urate-induced synovitis in dogs and adjuvant-induced polyarthritis in rats, both prophylactically and therapeutically. Preparation method and application of medicament-cyclodextrin inclusion compound self-emulsifying composition.
Thus according to an embodiment of the present invention, a method is provided for treatment of a COX-2 mediated disorder in a human subject comprising parenterally administering a composition as described herein to the subject at a Aceclofenac dosage equal to a therapeutically effective dosage of Diclofenac. Additionally a formulation of aceclofenac with arginine would give rise to a formulation with alkaline pH in which the aceclofenac would be instable unlike ibuprofen which is stable at alkaline pH.
Then it was filled in 2 ml vial of amber colored tubular glass and lyophilized. Such methods provide the present stable injectable pharmaceutical compositions of aceclofenac. Aceclofenac is a potent inhibitor of the formylation cyclooxygenase, which is involved in the production of prostaglandins.
System R f Drug in methanol 0. It can be downloaded free of cost for reference purpose. Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect. National Center for Biotechnology InformationU. The Aceclofenac formulation of claim 1wherein said Aceclofenac salt comprises a phenyl acetic acid derivative with anti-inflammatory analgesic properties. The reconstitution time was 8 sec for the developed lyophilized aceclofenac injection formulation.
The process of Item 26, wherein at least one of said aveclofenac aqueous solubilizer component and said Aceclofenac salt stabilizer component is polyethylene glycol. aceclofenav
The Aceclofenac formulation of claim 19 wherein said pharmaceutically effective dosage is provided in a sealed airtight container which is selected from the group consisting of a vial, an ampoule, a syringe, a packet, a pouch and an auto—injector. The solvent system was allowed to run for a height of about 4 cm. And when the molar ratio of arginine to aceclofenac is used within the specified limit of the present invention i.
The formulation was also studied for physical and chemical stability. X-ray diffractogram of the formulated lyophilized injection Formulation code: Continuous analysis of data from such monitoring permits filetupe of the treatment regimen during therapy so that optimally effective doses are administered at any point in time, and so that the duration of treatment can be determined.
In general, the present invention relates to formulqtion a stable injectable pharmaceutical composition comprising an aqueous solution of arginine and aceclofenac injectiob the molar ratio of arginine to aceclofenac in the range of about 1.
Rajkumar Gupta – Google+
A method of treating a subject having a acecoofenac or disorder wherein a treatment with NSAID is indicated, which method comprises parenterally administering a therapeutically effective amount of said nonaqueous liquid parenteral Aceclofenac formulation of Item 1. The composition has Aceclofenac salt stabilizing means for inhibiting precipitation of Aceclofenac. The solution was filtered through 0. Where a range; of values is provided, k is understood formulahion each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention.
Table 2 Equilibrium solubility of aceclofenac in different media. In order to check any interaction between drug and the hydrotropic agents, UV spectral studies of aceclofenac were performed in different hydrotropic solutions. Any known aceclofensc useful for parenteral injection of drugs can be used to effect such administration.
The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Received Feb; Accepted Mar. The Aceclofenac formulation of claim 1 aceclofeanc, wherein said formulation further comprises additional one or more nonaqueous solubilizer components, effective to stabilize said Aceclofenac and said Diclofenac that forms by conversion of said Aceclofenac component thereto, said additional nonaqueous solubilizer components being substantially inert with respect to said conversion.